Skip to content

Maker of anti-addiction drug Suboxone reaches $102.5 million settlement over antitrust claims

Suboxone is a branded version of buprenorphine and naloxone
32913396_web1_28750470-46c2b950fa0e42939ffe2ce176d9a621
FILE - In this Nov. 14, 2019, photo, Jon Combes holds his bottle of buprenorphine, a medicine that prevents withdrawal sickness in people trying to stop using opiates, as he prepares to take a dose in a clinic in Olympia, Wash. (AP Photo/Ted S. Warren, File)

The company that makes the opioid addiction treatment drug Suboxone has agreed to pay $102.5 million to 41 states and the District of Columbia to settle claims that the company engaged in anticompetitive practices, it announced Friday (June 2).

The agreement with Indivior, based in North Chesterfield, Virginia, averts a trial that was scheduled to start later this year.

States, led by Wisconsin, claimed that the company, previously a subsidiary of Reckitt Benckiser Pharmaceuticals, made modest changes to Suboxone to extend patent protection and keep generic versions of the drug off the market.

Suboxone

Support local journalism today

Join thousands of other like-minded readers and sign up below to gain immediate & unlimited access to our news for the next 30 days – plus start receiving our newsletters.

Sign Up with google Sign Up with facebook

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reset your password

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

A link has been emailed to you - check your inbox.



Don't have an account? Click here to sign up